Header Logo

Connection

Yuki Kageyama to Prostatic Neoplasms, Castration-Resistant

Back to Details
This is a "connection" page, showing publications Yuki Kageyama has written about Prostatic Neoplasms, Castration-Resistant.
Yuki Kageyama
Connection Strength
0.196
Prostatic Neoplasms, Castration-Resistant
  1. A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL). BMC Urol. 2023 Mar 06; 23(1):33.
    View in: PubMed
    Score: 0.196
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.